Element Biosciences

Description

Builds sequencing and multiomics platforms, including AVITI systems, to help laboratories access high-quality sequencing and spatial or single-cell biological analysis tools.

Element Biosciences is located in the San Diego ecosystem.

Related

• Illumina ($ILMN)Provides sequencing and array systems, reagents, software, services, financing, and training for laboratories and researchers conducting…
• Singular GenomicsBuilds a high-throughput spatial multiomics platform that maps RNA, proteins, and tissue morphology in FFPE samples for pathology and…
• J. Craig Venter InstituteAdvances genomics research, education, and policy work, using DNA sequencing, analysis, synthetic biology, and data tools for health,…
• Illumina AcceleratorProvides sequencing and microarray products, services, financing, monitoring, instrument support, and training resources for organizations…
• Ångström AIDevelops diagnostics using amplicon sequencing and machine learning, aiming to broaden access to sequencing-based diagnostic methods for…
• BennuBioMicrofluidic flow cytometry instruments for high-throughput single-cell analysis. UNM/LANL spin-out. HQ Albuquerque.
• HudsonAlpha Institute for BiotechnologyConducts biotechnology and genomic research, applies genomics to plant responses, provides whole-genome sequencing and analysis, and trains…
• Iambic TherapeuticsBuilds AI-driven drug discovery technologies and experimental platforms to design molecular candidates and generate biological data for…
• Avalon BioVenturesInvests in and builds biotech companies addressing unmet medical needs, providing portfolio teams with capital, expertise, mentorship,…
• EvoNexusRuns a startup incubation program for early-stage founders, offering residency, mentorship, investor access, and support with strategy,…
• Halozyme Therapeutics ($HALO)Develops subcutaneous drug delivery technologies, commercializes approved products using them, and partners with pharmaceutical companies…
• Kyverna Therapeutics (San Diego)Develops cell therapies for autoimmune disease patients, including an autologous CD19-targeting CAR T candidate being studied in ongoing…